Controversy exists over optimal management of low-risk differentiated thyroid cancer. This controversy occurs in all aspects of management, including surgery, use of radioactive iodine for remnant ablation, thyroid hormone supplementation, and long-term surveillance. Limited and conflicting data, treatment paradigm shifts, and differences in physician perceptions contribute to the controversy. This lack of physician consensus results in wide variation in patient care, with some patients at risk for over- or undertreatment. To reduce patient harm and unnecessary worry, there is a need to design and implement studies to address current knowledge gaps.

中文翻译：

---

低风险分化型甲状腺癌管理中的争议

关于低风险分化型甲状腺癌的最佳治疗存在争议。这种争议发生在管理的所有方面，包括手术，使用放射性碘进行残余消融，补充甲状腺激素和长期监测。有限且相互矛盾的数据，治疗范式的转变以及医师看法的差异助长了争议。缺乏医生共识的结果导致患者护理的差异很大，有些患者处于过度治疗或治疗不足的风险中。为了减少患者的伤害和不必要的担忧，需要设计和实施研究以解决当前的知识空白。